Can we cure antiphospholipid syndrome?

Area of Science:

• Immunology
• Rheumatology
• Vascular Biology

Background:

• Antiphospholipid antibody syndrome (APS) is characterized by recurrent thrombosis and pregnancy loss.
• Pathology is mediated by autoantibodies against phospholipid-binding proteins (aPL), primarily beta2glycoprotein I (β2GPI).
• Current treatments like anticoagulants and antiplatelet drugs are not universally effective, leading to treatment recurrences.

Purpose of the Study:

• To review current understanding of APS pathophysiology and treatment limitations.
• To explore novel therapeutic strategies targeting autoantibody production and immune mechanisms.
• To identify future research directions for improved APS management and potential cures.

Main Methods:

• Literature review and synthesis of current research on APS.
• Analysis of existing and emerging therapeutic targets and strategies.
• Discussion of preclinical and clinical findings related to novel APS treatments.

Main Results:

• Standard anticoagulant and antiplatelet therapies show limitations in preventing APS-related events.
• Conventional immunosuppression and B-cell therapies have not proven effective for aPL suppression.
• Emerging strategies like targeting CD38, anti-CD19 CAR-T cell therapy, and chimeric autoantigen receptor T cell therapy show promise.

Conclusions:

• There is a critical need for more effective APS therapies beyond current standards of care.
• Targeting autoantibody-producing cells, particularly via T-cell-based immunotherapies, represents a promising avenue.
• Further research into clot lysis and β2GPI/anti-β2GPI interactions may yield novel preclinical treatment approaches.